Eurofins Scientific company profile
Company profile
Eurofins Scientific has 65,000 employees and is headquartered in Luxembourg, Luxembourg.
Eurofins Scientific SE serves pharmaceutical and biotech companies, food and agriculture producers, consumer goods brands, environmental authorities and industrial clients across the world, offering analytical testing and laboratory services. Its work covers food and feed testing, environmental analysis of water, air, soil and waste, agroscience and seed services, consumer product and cosmetics testing, electrical and electronics laboratories, clinical and in vitro diagnostics, forensic and genomic services, and REACH chemical compliance. Its operations span many countries, and the company was founded in 1987.
In the fiscal year ended December 2025, the company reported revenue of EUR 7.3 billion, up 5.0% from the previous year, and net income of EUR 474.8 million. It employed 65,000 people and is headquartered in Luxembourg, Luxembourg.
Company facts
- Sector
- Industrials
- Industry
- Diagnostics & Research
- Country
- France
- Headquarters
- 23 Val Fleuri, 1526, Luxembourg
- Employees
- 65,000
- Chief executive
- Gilles Martin
- Founded
- 1987
- Fiscal year
- January - December
- Listing
- ERF · Euronext Paris
- Indices
- CAC 40
- Currency
- EUR
- ISIN
- FR0014000MR3
- Website
- eurofins.com
Eurofins Scientific and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Eurofins ScientificERF | France | $16.03B | 65,000 | 14.1% | 29.6 |
| bioMérieuxBIM | France | $11.82B | 14,562 | 16.0% | 23.4 |
| QiagenQIA | Germany | $10.23B | 5,400 | 26.7% | 28.5 |
| Lonza GroupLONN | Switzerland | $54.2B | 20,141 | 23.5% | 43.2 |
| DiaSorinDIA | Italy | $4.21B | 3,212 | 22.3% | 28.6 |
| DiagnostykaDIA | Poland | $1.27B | 8,645 | 14.9% | 20.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
